Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall, Merck (MSD), Hikma, China Medical System, Dermavon - LARVOL DELTA

Predictors of PASI Response to Tildrakizumab: Insights from Elastic Net Modeling of Pooled Phase 3 Trials (ACR Convergence 2026) - No abstract available

P3 data • Ankylosing Spondylitis • Immunology • Psoriasis • Psoriatic Arthritis • Rheumatology • Spondylarthritis

Baseline Predictors of ACR Response to Tildrakizumab in Patients with Psoriatic Arthritis: An Elastic Net Analysis of Pooled Phase 3 Trials (ACR Convergence 2026) - No abstract available

Clinical • P3 data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Efficacy and Safety of Tildrakizumab in Anti-TNF-Naïve Patients With Active Psoriatic Arthritis: Week 52 Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (ACR Convergence 2026) - No abstract available

Clinical • P3 data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Comparative Pancreatitis Safety Signal of IL-17 Versus IL-23 Inhibitors: A FAERS Pharmacovigilance Study (ACG 2026) - "Reports containing the preferred term âpancreatitisâ were identified for IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab) and IL-23 inhibitors (guselkizumab, risankizumab, tildrakizumab). 707 cases of pancreatitis were reported. Among IL-17 inhibitors, 385 reports were associated with secukinumab, 43 with ixekizumab, and 19 with bimekizumab. Secukinumab demonstrated a significant disproportionality signal [ROR 1.379 (95% CI 1.248â1.525); PRR 1.378; ϲ 39.8; p< 0.05]."

Adverse events • Clinical • Immunology • Inflammation • Inflammatory Arthritis • Pancreatitis • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies • IL17A • IL23A • ROR1

A Holistic View of Treatment Success in Psoriasis: Long-Term Real-World Improvements in Psychological Well-Being and Health-Related Quality of Life with Tildrakizumab in Patients with Psoriasis and Burdensome Symptoms (POSITIVE study) (EADV 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis

Facial psoriasis succesfully treated with tildrakizumab (EADV 2026) - No abstract available

Dermatology • Immunology • Psoriasis

Real-world effectiveness, safety and clinical impact of dose escalation of tildrakizumab in moderate-to-severe psoriasis (EADV 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Dermatology • Immunology • Psoriasis

Pro-inflammatory cytokine reduction in psoriasis patients treated withtildrakizumab, brodalumab and methotrexate: A prospective study. (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

Long-term effectiveness and safety of tildrakizumab in a patient with severe psoriasis and metabolic comorbidities (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

Modulation of leukemia inhibitory factor (LIF) pathway in patients treated with tildrakizumab, brodalumab and methotrexate: A potential marker of cardiovascular inflammation improvement under tildrakizumab treatment. (EADV 2026) - No abstract available

Clinical • Hematological Malignancies • Leukemia • LIF

BADBIR Patient characteristics of biologic-experienced and biologic-naive patients with chronic plaque psoriasis receiving tildrakizumab (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Two birds, one stone: Concurrent control of chronic plaque psoriasis and pouchitis with tildrakizumab therapy (EADV 2026) - No abstract available

Dermatology • Gastrointestinal Disorder • Immunology • Inflammation • Plaque Psoriasis • Psoriasis

Achieving sustained disease control in complex patients through tailored treatment with tildrakizumab (EADV 2026) - "This session is sponsored by: Almirall"

Clinical • Dermatology • Dermatopathology • Immunology • Psoriasis

Resolution of Secukinumab/Guselkumab-Induced Long-Term Paradoxical Eczematous Eruptions After Switching to Tildrakizumab Treatment. (PubMed, J Dermatol) - No abstract available

Journal • Atopic Dermatitis • Dermatology • Immunology

Psycholag in Moderate-to-Severe Psoriasis: Insights from the POSITIVE Study on Psychological Well-Being and Treatment with Tildrakizumab (EADV 2026) - No abstract available

Dermatology • Immunology • Psoriasis

Holistic Treatment Success with Tildrakizumab: Combined Evidence of WHO‑5, PASI and DLQI Outcomes from the POSITIVE, BLUE, TiGER, TIL‑TWO and TIL‑Senior Studies (EADV 2026) - No abstract available

Dermatology • Dermatopathology • Immunology • Psoriasis

High effectiveness of tildrakizumab in moderate-to-severe psoriasis regardless of prior biologic, lines of therapy, or disease duration: 28-week interim data from the PROCARE-T study (EADV 2026) - No abstract available

Dermatology • Immunology • Psoriasis

Comparative efficacy and safety of IL-23 p19 monoclonal antibodies for plaque psoriasis: a bayesian network meta-analysis of randomized controlled trials. (PubMed, Front Immunol) - "We included randomized controlled trials of guselkumab, risankizumab, tildrakizumab, or mirikizumab. Head-to-head trials and long-term real-world studies are needed. https://www.crd.york.ac.uk/PROSPERO, identifier CRD420261382915."

Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Psoriasis • IL23A

Spatial dynamics of regulatory T cells and tissue-resident memory T cells during IL-23 inhibition with tildrakizumab in psoriasis (EADV 2026) - No abstract available

Dermatology • Immunology • Psoriasis • IL23A

Psoriasis, Obesity, and Targeted Therapy: Combined Tildrakizumab and Semaglutide Treatment (EADV 2026) - No abstract available

Dermatology • Genetic Disorders • Immunology • Obesity • Psoriasis

Beyond the Blockade: Unmasking the Adverse Event Profile of Tildrakizumab (ACR Convergence 2026) - No abstract available

Adverse events

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio study): An International, Pragmatic, Multicentre, Randomised, Controlled, Non-Inferiority Trial. (PubMed, Lancet Reg Health Eur) - P4 | "Patients with stable low disease activity on registered dosages of IL17i (secukinumab, ixekizumab, bimekizumab, brodalumab) or IL23i (guselkumab, risankizumab, tildrakizumab) were eligible. Disease-activity guided, stepwise interval prolongation of IL17i and IL23i in patients with controlled psoriasis is an effective and safe strategy to reduce unnecessary exposure to these expensive drugs. ZonMw (the Netherlands Organization for Health Research and Development), KCE Trials (the Belgian Health Care Knowledge Centre)."

Head-to-Head • Journal • Dermatology • Immunology • Psoriasis • IL17A

Association Between Psoriasis Duration and Maintenance of Control (PASI ≤2) after Tildrakizumab Withdrawal: Post Hoc Analyses from reSURFACE 1 (EADV 2026) - No abstract available

Clinical • Retrospective data • Dermatology • Immunology • Psoriasis

Health-Related Quality of Life, Work Productivity and Treatment Satisfaction with Tildrakizumab for Up to 2 Years in Patients with Moderate-to-Severe Psoriasis in the POSITIVE Study (EADV 2026) - No abstract available

Clinical • HEOR • Dermatology • Immunology • Psoriasis

High effectiveness of tildrakizumab 200 mg over 2 years in patients with severe psoriasis: a Belgian two-centre real-world study (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis